Empagliflozin is a mildly effective hypoglycemic with diuretic properties. It has shown benefit in type 2 diabetes patients with existing cardiovascular disease (including heart failure) and chronic kidney disease (glomerular filtration rate 45-59 mL/min).

**Initiation (new start) criteria:** Non-formulary **empagliflozin (Jardiance)** will be covered on the prescription drug benefit when the following criteria are met:

- Diagnosis of type 2 diabetes, and
- Patient has a recent HbA1c under 8.5, and
- On maximally tolerated metformin dose (1500-2500mg) for at least 3 months (or allergy or intolerance* to metformin), and
- One or more of the following 3 qualifying conditions:
  1. Atherosclerotic Cardiovascular Disease (ASCVD) [conditions include: acute coronary syndromes (ACS), history of myocardial infarction (MI), stable or unstable angina, coronary or other arterial revascularization, ischemic stroke, transient ischemic attack (TIA), or symptomatic peripheral arterial disease (PAD)]
     a. And on maximally tolerated dose or patient has an allergy or intolerance* to statin
     b. And on maximally tolerated dose or patient has an allergy or intolerance* to ACE/ARB
  2. Chronic Kidney Disease
     a. GFR between 45 and 59 mL/min
     b. And on maximally tolerated dose or patient has an allergy or intolerance* to statin
     c. And on maximally tolerated dose or patient has an allergy or intolerance* to ACE/ARB
  3. Heart Failure
     a. And on maximally tolerated dose or patient has an allergy or intolerance* to statin
     b. And on maximally tolerated dose or patient has an allergy or intolerance* to ACE/ARB
     c. And on maximally tolerated dose or patient has an allergy or intolerance* to beta blocker

* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation